Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announces-Pricing-of-Upsized-350-Million-Convertible-Senior-Notes-Offering/default.aspx
Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announced-Proposed-Offering-of-330-Million-of-Convertible-Senior-Notes/default.aspx
Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Announced-Proposed-Offering-of-330-Million-of-Convertible-Senior-Notes/default.aspx
Ironwood Pharmaceuticals Reports Second Quarter 2019 Results
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2019-Results/default.aspx
Ironwood Pharmaceuticals Reports Second Quarter 2019 Results
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2019-Results/default.aspx
Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2019-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2019-Investor-Update-Call/default.aspx
Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-and-Allergan-Report-Positive-Topline-Data-from-Phase-IIIb-Trial-of-LINZESS-linaclotide-in-Adults-with-Irritable-Bowel-Syndrome-with-Constipation-IBS-C/default.aspx
Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-and-Allergan-Report-Positive-Topline-Data-from-Phase-IIIb-Trial-of-LINZESS-linaclotide-in-Adults-with-Irritable-Bowel-Syndrome-with-Constipation-IBS-C/default.aspx
Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston
https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-to-Establish-New-Headquarters-in-Downtown-Boston/default.aspx